Publikation

Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial.

Wissenschaftlicher Artikel/Review - 02.09.2022

Bereiche
PubMed
DOI
Kontakt

Zitation
Shoamanesh A, Mundl H, Smith E, Masjuan J, Milanov I, Hirano T, Agafina A, Campbell B, Caso V, Mas J, Dong Q, Turcani P, Christensen H, Ferro J, Veltkamp R, Mikulik R, De Marchis G, Robinson T, Lemmens R, Stepien A, Greisenegger S, Roine R, Csiba L, Khatri P, Coutinho J, Lindgren A, Demchuk A, Colorado P, Kirsch B, Neumann-Haefelin C, Heenan L, Xu L, Connolly S, Hart R, PACIFIC-Stroke Investigators. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet 2022; 400:997-1007.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Lancet 2022; 400
Veröffentlichungsdatum
02.09.2022
eISSN (Online)
1474-547X
Seiten
997-1007
Kurzbeschreibung/Zielsetzung

Asundexian (Bayer AG, Leverkusen, Germany), an oral small molecule factor XIa (FXIa) inhibitor, might prevent thrombosis without increasing bleeding. Asundexian's effect for secondary prevention of recurrent stroke is unknown.